PAC4462 - Integrated therapeutics: Neurology and oncology - 2019

6 points, SCA Band 2, 0.125 EFTSL

Undergraduate - Unit

Refer to the specific census and withdrawal dates for the semester(s) in which this unit is offered.

Faculty

Pharmacy and Pharmaceutical Sciences

Chief examiner(s)

Professor Colin Pouton

Coordinator(s)

Professor Colin Pouton (Parkville)
Ali Qais Blebil (Malaysia)

Unit guides

Offered

Malaysia

  • Second semester 2019 (On-campus)

Parkville

  • Second semester 2019 (On-campus)

Prerequisites

PAC4451

Synopsis

This unit aims to lay a foundation of knowledge about diseases and disorders in neurology and oncology and to provide the relationship between pathophysiology and the rational design and use of drugs in the management of conditions of this type.

The chemistry, pharmacology and clinical aspects of medications associated with each area are presented in detail in an integrated fashion.

Drug therapy principles for particular conditions and patient groups will be emphasised enabling students to acquire the skills necessary to provide clinical pharmacy services within these areas.

Specifically the unit will cover epilepsy, migraine, multiple sclerosis, Parkinson's disease, stroke and a range of common malignancies such as breast cancer, prostate cancer, bowel cancer, skin cancer, leukaemia, lung cancer, etc.

It will also deal with principles of palliative care and management of patients at the end of life.

Students will perform a number of tasks which will help with the development of critical thinking skills and oral and/or written communication skills.

Outcomes

  1. This unit aims to lay a foundation of knowledge about diseases and disorders in neurology and oncology and to provide the relationship between pathophysiology and the rational design and use of drugs in the management of conditions of this type.
  2. The chemistry, pharmacology and clinical aspects of medications associated with each area are presented in detail in an integrated fashion.
  3. Drug therapy principles for particular conditions and patient groups will be emphasised enabling students to acquire the skills necessary to provide clinical pharmacy services within these areas.
  4. Specifically the unit will cover epilepsy, migraine, multiple sclerosis, Parkinson's disease, stroke and a range of common malignancies such as breast cancer, prostate cancer, bowel cancer, skin cancer, leukaemia, lung cancer, etc. It will also deal with principles of palliative care and management of patients at the end of life.
  5. Students will perform a number of tasks which will help with the development of critical thinking skills and oral and written communication skills.

Assessment

Final exam: 60%; in-semester MCQ or short answer tests: 20%; laboratory assessments (case-based exercises): 20%

Workload requirements

Contact hours for on-campus students:

  • Thirty six 1-hour lectures or equivalent, delivered face to face or online
  • Directed tasks in the form of online group exercises (equivalent to two 6-hour exercises)

See also Unit timetable information

Additional information on this unit is available from the faculty at: